(Q37077619)

18 August 2017

1 reference

title

What is in the pipeline for Gram-negative pathogens? (English)

1 reference

18 August 2017

main subject

gram-negative bacteria

0 references

author name string

George H Talbot

series ordinal

1

1 reference

18 August 2017

publication date

1 February 2008

1 reference

Expert Review of Anti-infective Therapy

18 August 2017

published in

1 reference

18 August 2017

volume

6

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

39-49

1 reference

Reemergence of macrolide resistance in pharyngeal isolates of group a streptococci in southwestern Pennsylvania

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (199

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Tigecycline: a critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Peptide antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.39

21 January 2018

Identifiers

DOI

10.1586/14787210.6.1.39

1 reference

18 August 2017

1 reference